This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: C10 (C10.0 lingual surface of epiglottis, C10.1 anterior epiglottic fold, C10.2 posterior pharyngeal wall, C10.3 lateral pharyngeal wall, C10.4 branchial cleft origin, C10.8 overlapping sites, C10.9 unspecified) | Special Copayment Reduction: V193 (5% copayment for care of the relevant condition for 5 years from the cancer patient registration date) |
| B. Synonyms | Oropharyngeal cancer, cancer of the oropharynx, oropharyngeal squamous cell carcinoma; Oropharyngeal carcinoma, Oropharyngeal squamous cell carcinoma (OPSCC), Pharyngeal wall carcinoma, Posterior pharyngeal wall cancer |
| C. Adult onset | Likelihood of first onset in adulthood very high — mostly diagnosed in their 40s–70s; HPV+ oropharyngeal cancer is increasing among nonsmoking men aged 45–65 |
| 1. History | Establishment of surgery and radiotherapy for oropharyngeal cancer in the 20th century, rapid epidemiologic change in the 21st century due to the HPV epidemic, introduction of separate HPV staging in AJCC 8th edition |
| 2. Causes | HPV-16 (main cause, 60–80% in North America and the West), smoking and alcohol (main causes of HPV– oropharyngeal cancer), immunosuppression |
| 3. Genetics | HPV+: E6/E7, p53, Rb, PIK3CA, TRAF3; HPV–: TP53, CDKN2A, FAT1, NOTCH1, CASP8; PD-L1 CPS and TMB as markers for immunotherapy |
| 4. General epidemiology | Rapid worldwide increase in oropharyngeal cancer (HPV epidemic), increasing among head and neck cancers in Korea, includes tonsil, base of tongue, posterior pharyngeal wall, and soft palate, male predominance |
| 5. Pathophysiology | Oropharyngeal mucosal HPV infection and carcinogenesis by E6/E7 oncoproteins; smoking-mediated multistep carcinogenesis; EGFR, PI3K, Wnt, and Notch pathways; immunogenic tumor microenvironment |
| 6. Symptoms | Sore throat, odynophagia, otalgia (referred pain), halitosis, cystic neck mass; depending on site, breathing difficulty with epiglottic involvement and dysphagia with posterior pharyngeal wall tumors |
| 7. Signs | Posterior/lateral pharyngeal wall mass, enlarged cervical level II/III lymph nodes (cystic or solid), laryngoscopic findings, parapharyngeal space invasion on CT/MRI |
| 8. Screening | Otolaryngologic endoscopic examination, visual inspection of the oropharynx, HPV vaccine (prevention), intensive surveillance of high-risk groups |
| 9. Diagnosis | CT/MRI/PET-CT, endoscopy/panendoscopy, p16/HPV testing, separate HPV+ staging in AJCC 8th edition, protocol for workup of unknown primary cancer |
| 10. Treatment | CRT (cisplatin + IMRT standard), TORS, de-escalation (HPV+ studies), pembrolizumab (KEYNOTE-048), nivolumab (CheckMate 141), TAX 324 induction chemotherapy |
| 11. Prognosis | HPV+ 5-year survival 80–90%, HPV– 40–55%; smoking history, T stage, N stage, ENE, and resection margins are key prognostic factors; management of functional complications is important |
| 12. Prevention | 9-valent HPV vaccine (key), smoking cessation and moderation of alcohol intake, oral hygiene, regular otolaryngologic checkups, education on safe sexual behavior |
| 13. References | Burtness B et al. KEYNOTE-048. The Lancet. 2019 ... and 9 other papers |
The oropharynx is the part of the pharynx extending from the back of the oral cavity to the upper larynx; anatomically it includes the tonsil (C09), base of tongue (C01), and soft palate (C05.1), and ICD-10 code C10 refers to the remaining oropharyngeal sites excluding these—namely the lingual surface of the epiglottis, glosso-epiglottic fold, posterior pharyngeal wall, and lateral pharyngeal wall. Clinically, oropharyngeal cancer is often used as a broad concept covering all of these sites.
In the early 20th century, radiotherapy was preferred for oropharyngeal cancer mainly because its anatomic features made surgical access difficult. For posterior and lateral pharyngeal wall cancers, wide resection is difficult because of anatomic proximity to the pharyngeal muscles and pharyngeal constrictors, so radiotherapy became the mainstay. The introduction of cisplatin in the mid-20th century made it possible to establish concurrent chemoradiotherapy (CRT), which became the standard treatment for oropharyngeal cancer.
Since the 2000s, the epidemiology of oropharyngeal cancer has changed fundamentally with the HPV epidemic. Following the pioneering work of Gillison et al., numerous prospective studies confirmed the excellent treatment response and survival of HPV-positive oropharyngeal cancer, leading to the introduction in 2017 of separate TNM staging for HPV-positive and HPV-negative oropharyngeal cancer in AJCC 8th edition. In addition, de-escalation clinical trials seeking to minimize treatment toxicity while maintaining equivalent oncologic outcomes in HPV+ oropharyngeal cancer are being actively conducted worldwide.
The introduction of immunotherapy (pembrolizumab, nivolumab) greatly expanded the treatment options for recurrent/metastatic oropharyngeal cancer. In particular, in the KEYNOTE-048 study, pembrolizumab showed better overall survival than the existing EXTREME combination regimen and was established as the new first-line standard of care. In Korea as well, immunotherapy has been approved for National Health Insurance coverage, improving access to treatment for patients with oropharyngeal cancer.
HPV-16 is the most important cause of oropharyngeal cancer (including C10); in North America and Western Europe, 60–80% of oropharyngeal cancers are HPV-related. In Korea this proportion is lower but increasing. Oral infection with HPV-16 raises the risk of oropharyngeal cancer about 15-fold or more and is transmitted mainly through oral sex. Multiple sexual partners and experience of oral sex are risk factors.
In HPV-negative oropharyngeal cancer, smoking and alcohol are the main causes. Tobacco carcinogens act directly on the oropharyngeal mucosa, and alcohol promotes a carcinogenic environment. Combined exposure to smoking and alcohol causes a synergistic increase in risk. Smoking also worsens the prognosis of HPV-positive oropharyngeal cancer.
Immunosuppression after organ transplantation, HIV infection, and poor oral hygiene are ancillary risk factors. For posterior pharyngeal wall cancer, chronic reflux esophagitis has also been suggested as a risk factor in some studies.
When HPV viral DNA integrates into the host genome, the E6 and E7 oncoproteins are continuously expressed. E6 degrades TP53, and E7 inactivates the Rb protein, inducing escape from the cell cycle. As a result, p16 (CDKN2A) is reactively overexpressed, so p16 immunohistochemistry is used as a surrogate marker for HPV. PIK3CA activating variants (about 30–50%), TRAF3 deletion, and E2F1 amplification are characteristic. HPV+ tumors are rich in TILs and have high PD-L1 expression, making them more sensitive to immunotherapy.
TP53 (60–80%), CDKN2A deletion, and FAT1, NOTCH1, CASP8, and HRAS variants are common. EGFR overexpression is prominent and provides the theoretical rationale for cetuximab use. Variants of epigenetic regulatory genes such as KMT2D (histone methylation regulation) and NSD1 are also observed.
PD-L1 CPS is central to determining eligibility for pembrolizumab (CPS≥1: monotherapy; CPS≥20: greater benefit). TMB (tumor mutational burden) and MMR deficiency are also being studied as predictors of response to immunotherapy. Pretreatment PD-L1 CPS, TMB, and MMR testing are recommended in the NCCN guidelines (v1.2026).
According to GLOBOCAN 2022, oropharyngeal cancer (including tonsil, base of tongue, soft palate, pharyngeal wall, etc.) occurs in several hundred thousand people worldwide each year and is increasing rapidly in North America and Western Europe due to the HPV epidemic. In the United States, oropharyngeal cancer surpassed cervical cancer in incidence in the 2010s and became the most common HPV-related cancer in men.
According to Korean National Cancer Center data and academic studies, between 1999 and 2012 the incidence of oropharyngeal cancer (including tonsil and base of tongue) showed the steepest increase among head and neck cancers. In the site distribution of head and neck squamous cell carcinoma, the oropharynx (tonsil, base of tongue) is gradually emerging as a major site. There is a male predominance (about 3:1), and the main age of onset is the 40s–70s.
Posterior and lateral pharyngeal wall cancers corresponding to C10 account for about 10–20% of all oropharyngeal cancers. Posterior pharyngeal wall cancer responds relatively well to radiotherapy but has a high risk of metastasis to bilateral cervical and retropharyngeal lymph nodes.
HPV-16 infects the basal cells of the nonkeratinized squamous epithelium of the oropharyngeal mucosa, and viral DNA integrates into the host genome. The E6/E7 oncoproteins are continuously expressed, destroying cell-cycle regulatory function and inducing cell immortalization and tumorigenesis. The lymphoid-rich structures of the oropharynx (tonsillar crypts, oropharyngeal mucosa-associated lymphoid tissue) facilitate HPV access to the basal epithelium.
Carcinogens in tobacco smoke accumulate in the oropharyngeal mucosa and induce mutations in tumor suppressor genes such as TP53, CDKN2A, and FAT1. This multistep carcinogenic process progresses through precancerous lesions (dysplasia) to invasive cancer.
Hyperactivation of the EGFR/RAS/MAPK, PI3K/AKT/mTOR, Wnt/β-catenin, and Notch pathways promotes cell proliferation, invasion, and angiogenesis. In the tumor microenvironment, immunosuppressive cells (Treg, MDSC) and cytokines (TGF-β, IL-10) suppress antitumor immunity, but HPV+ tumors are rich in TILs and relatively more immunogenic.
The early symptoms of oropharyngeal cancer are nonspecific. Sore throat, foreign body sensation on swallowing, and mild odynophagia are the most common early symptoms. Unilateral symptoms (one-sided sore throat, one-sided otalgia) are diagnostically important. Referred otalgia occurs via the glossopharyngeal nerve (CN IX), and oropharyngeal cancer should be suspected when the patient complains only of ear pain without unilateral throat symptoms.
HPV-positive oropharyngeal cancer metastasizes early to cervical lymph nodes even when the primary tumor is small, so a cystic neck mass commonly presents as the first symptom. Posterior pharyngeal wall cancer causes a foreign body sensation on swallowing, eating difficulties, and voice changes relatively early. With involvement of the lingual surface of the epiglottis, odynophagia is prominent and the risk of aspiration increases.
In advanced oropharyngeal cancer, severe dysphagia, trismus (pterygoid muscle invasion), cranial nerve palsies (parapharyngeal invasion), airway symptoms, and weight loss appear. When lateral pharyngeal wall cancer invades the parapharyngeal space and skull base, multiple cranial nerve palsies (CN IX, X, XI, XII) may occur.
The posterior pharyngeal wall, lateral wall, and lingual surface of the epiglottis are systematically observed with flexible laryngoscopy. The tumor appears as an exophytic or endophytic ulcerative mass. With involvement of the lingual surface of the epiglottis, deformity of the epiglottis and vallecular pooling are observed. Parapharyngeal space invasion presents as unilateral pharyngeal bulging.
Enlargement of ipsilateral cervical level II/III lymph nodes is the most common. Posterior pharyngeal wall cancer metastasizes to the retropharyngeal lymph nodes, which are identified on CT. The cystic cervical lymph nodes characteristic of HPV+ oropharyngeal cancer are identified on ultrasound and CT.
CT shows an enhancing mass in the oropharynx and cervical lymph node metastasis. MRI is essential for evaluating invasion of the parapharyngeal space, prevertebral soft tissue, and skull base. PET-CT is standard for workup of unknown primary cancer and evaluation of distant metastasis.
Systematic inspection of the entire oropharynx using a flexible endoscope is key to early detection of oropharyngeal cancer. Patients with unilateral throat abnormalities, otalgia, or a neck mass in particular require immediate endoscopy. If irregular mucosal changes, erythema, or ulcers are found in the oropharynx, a biopsy is performed.
When a patient presents with cystic cervical lymph nodes as the main symptom, HPV-positive oropharyngeal cancer is likely to be the primary tumor. In this case, PET-CT, MRI, panendoscopy, tonsillectomy (ipsilateral or bilateral), and histopathologic examination are performed to identify the primary site.
The 9-valent HPV vaccine, which covers HPV-16 and other types, is expected to be effective in preventing HPV-related oropharyngeal cancer. Currently, along with national vaccination of adolescent girls, expansion of vaccination to boys and adults is recommended.
CT (contrast-enhanced): evaluates oropharyngeal tumor size and location, cervical lymph node metastasis, and bone invasion. When cystic lymph nodes are seen, HPV+ oropharyngeal cancer is strongly suspected. MRI (T1, T2, contrast-enhanced): essential for evaluating invasion of the parapharyngeal space, skull base, perineural spread, and prevertebral soft tissue. PET-CT: standard for workup of unknown primary cancer and evaluation of distant metastasis and cervical lymph node metastasis.
The entire oropharynx is observed with flexible laryngoscopy, and suspicious lesions are biopsied. Panendoscopy includes laryngoscopy, bronchoscopy, and esophagoscopy and is essential to rule out metachronous primary tumors. In the workup of unknown primary cancer, extended panendoscopy including bilateral tonsillectomy and biopsy of the base of tongue is performed.
HPV status is first assessed by p16 immunohistochemistry (strong and diffuse, ≥70% of tumor cells positive) and confirmed by HPV DNA ISH or PCR. In AJCC 8th edition, HPV-positive oropharyngeal cancer is staged under a separate classification with a less stringent N classification (ENE criterion excluded). HPV-negative oropharyngeal cancer follows the traditional head and neck TNM.
Concurrent chemoradiotherapy (CRT) is the first-line standard treatment for locally advanced (stage III–IV) oropharyngeal cancer. With IMRT/VMAT, 66–70 Gy is prescribed to the primary tumor and metastatic lymph nodes, 60 Gy to high-risk prophylactic areas, and 54–56 Gy to low-risk prophylactic areas. Cisplatin (100 mg/m², every 3 weeks) is the standard agent for concurrent chemotherapy. When nephrotoxicity or ototoxicity is a concern, it is replaced with carboplatin or cetuximab.
In very locally advanced oropharyngeal cancer, the strategy of giving TPF (docetaxel + cisplatin + 5-FU) induction chemotherapy first to reduce tumor burden, followed by CRT, showed a survival benefit in the TAX 324 study.
Transoral robotic surgery (TORS) is effective for early oropharyngeal cancer. Adjuvant radiotherapy or CRT is given according to postoperative pathologic findings.
De-escalation studies that reduce treatment intensity by taking advantage of the excellent treatment response of HPV+ oropharyngeal cancer are active. Strategies such as radiation dose reduction (54–60 Gy), omission of radiation after TORS, and use of cetuximab instead of cisplatin are being tested in clinical trials (ECOG-3311, ORATOR, HN002, MC1273). Currently, de-escalation is recommended only within clinical trials.
Based on KEYNOTE-048, pembrolizumab alone (CPS≥1) or pembrolizumab + cisplatin/carboplatin + 5-FU combination is the first-line standard of care. The clinical benefit of pembrolizumab alone is greater with CPS≥20. Based on CheckMate 141, nivolumab is second-line treatment after platinum failure. Cetuximab + EXTREME combination is also a first-line option. The NCCN guidelines (v1.2026) recommend pretreatment PD-L1 CPS, TMB, and MMR testing.
| HPV status | 5-year overall survival rate | Key features |
|---|---|---|
| HPV-positive | About 80–90% | Excellent response to CRT even in locally advanced disease; high success rate of salvage treatment after recurrence |
| HPV-negative | About 40–55% | Smoking-related; risk of multiple primary tumors; poor prognosis on recurrence |
HPV status is the most important prognostic factor. Smoking history (smoking worsens prognosis especially in HPV+ patients), T stage, N stage (especially number of lymph nodes and presence of ENE), and margin status are independent prognostic factors. Parapharyngeal space invasion and skull base invasion are associated with a poor prognosis.
Dysphagia, xerostomia, trismus, and weight loss are long-term complications after CRT. With the introduction of IMRT, salivary gland dose has decreased, partly improving xerostomia. Swallowing rehabilitation, speech therapy, and nutritional support should be integrated into the treatment plan. Recovery of swallowing function tends to be faster after TORS.
9-valent HPV vaccination is central to preventing (HPV-related) oropharyngeal cancer. In Korea's national immunization program it is given to girls aged 12, and expansion of vaccination to boys and adults is needed. The preventive effect is greatest when given before sexual debut. Smoking cessation is essential for preventing HPV-negative oropharyngeal cancer and improving the prognosis of HPV-positive patients. Systematic smoking cessation support for smokers (counseling, pharmacotherapy) is important. Moderation of alcohol intake also contributes to reducing the risk of oropharyngeal cancer. Education on safe sexual behavior (condom use, limiting the number of partners) helps reduce oral HPV transmission.
Visual inspection of the oropharynx is performed at regular otolaryngologic checkups (at least once a year). A cystic neck mass, unilateral throat symptoms, or otalgia requires immediate specialist referral and PET-CT and endoscopy. Regular otolaryngologic checkups are performed in high-risk groups (smokers and drinkers, immunosuppressed patients, people with multiple sexual partners).
Chemoprevention with retinoids, COX-2 inhibitors, and the like is being studied in oropharyngeal precancerous lesions but has not been established as a clinical standard. Maintaining oral hygiene and regular dental checkups also contribute to maintaining the health of the oropharyngeal mucosa.
Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. The Lancet. 2019;394(10212):1915-1928. DOI: 10.1016/S0140-6736(19)32591-7
Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck (CheckMate 141). New England Journal of Medicine. 2016;375(19):1856-1867. DOI: 10.1056/NEJMoa1602252
Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma. Journal of Clinical Oncology. 2015;33(29):3235-3242. DOI: 10.1200/JCO.2015.61.6995
Amin MB, Edge S, Greene F, et al. (eds). AJCC Cancer Staging Manual, 8th Edition. Springer. 2017. ISBN: 978-3-319-40617-6.
National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers. Version 1.2026. NCCN. 2025. Available at: https://www.nccn.org
Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer (TAX 324). New England Journal of Medicine. 2007;357(17):1705-1715. DOI: 10.1056/NEJMoa070956
Marur S, D'Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. The Lancet Oncology. 2010;11(8):781-789. DOI: 10.1016/S1470-2045(10)70017-6
Park JO, Joo YH, Jung CK, et al. Trends in Head and Neck Cancer in South Korea Between 1999 and 2012. JAMA Otolaryngology–Head & Neck Surgery. 2016;142(12):1157-1165. DOI: 10.1001/jamaoto.2016.2396
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022. CA: A Cancer Journal for Clinicians. 2024;74(3):229-263. DOI: 10.3322/caac.21834
Kim M, Kim JH, Kim JY, et al. An epidemiological trend analysis of oral cancer in Korea from 2001 to 2021. BMC Oral Health. 2025;25:567. DOI: 10.1186/s12903-025-06351-1